Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
BPH Impact IndexBosniak ClassificationCAPRA ScoreD'Amico Risk ClassificationEAU NMIBC Risk Groups (2021)EORTC Risk Tables for NMIBCFournier's Gangrene Severity IndexGUPI (Genitourinary Pain Index)Guy's Stone ScoreICIQ-UI SFIGCCCG ClassificationIIEF-5 / SHIMIIQ-7IMDC (Heng) Risk CriteriaIPSS ScoreNIH-CPSIOAB-V8PADUA Prediction ScorePI-RADS v2.1PSA DensityR.E.N.A.L. Nephrometry ScoreResidual Volume (PVR)S.T.O.N.E. NephrolithometrySFU Hydronephrosis GradingUDI-6VUR Grading
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Recent Journal Updates

FDA MedWatchJun 16, 2026
Early Alert: Convenience Kit Issue from Windstone Medical Packaging, Inc.

Clinical Context

We think this might be relevant to the clinical guidance for S.T.O.N.E. Nephrolithometry Score.

WHO NewsJun 15, 2026
Open letter to leaders of G7, G20, BRICS and all nations on finalizing the WHO Pandemic Agreement’s Pathogen Access and Benefit Sharing annex

Clinical Context

We think this might be relevant to the clinical guidance for S.T.O.N.E. Nephrolithometry Score.

FDA MedWatchJun 10, 2026
FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury

Clinical Context

We think this might be relevant to the clinical guidance for S.T.O.N.E. Nephrolithometry Score.

S.T.O.N.E. Nephrolithometry

PCNL Stone Complexity — CT-Based Scoring

S.T.O.N.E. Parameters

Awaiting Selections

Select all 5 parameters from preoperative CT imaging.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

When to Use the S.T.O.N.E. Nephrolithometry Score

Preoperative planning and risk stratification for patients undergoing percutaneous nephrolithotomy (PCNL)
Prediction of stone-free rate (SFR) after a single PCNL procedure
Counseling patients regarding expected success rates and potential need for staged or auxiliary procedures
Surgical decision-making: choice of access (supine vs prone), number of tracts, and operative time estimation
Comparison of outcomes between different centers and surgeons
Research and audit of PCNL results
Selection between PCNL and alternative modalities (RIRS, SWL) in complex stones
Identifying high-complexity cases that may benefit from referral to high-volume endourology centers

Clinical Context

Percutaneous nephrolithotomy remains the gold-standard treatment for large renal stones (>2 cm), staghorn calculi, and stones with unfavorable anatomy for retrograde intrarenal surgery. Stone complexity significantly affects stone-free rates, operative time, radiation exposure, blood loss, and complication rates. The S.T.O.N.E. score was developed as a simple, reproducible, CT-based tool that quantifies five key parameters to predict PCNL outcomes more objectively than subjective judgment alone.

Advantages of S.T.O.N.E. Score

Based entirely on preoperative non-contrast CT (NCCT) — no additional imaging required
Quick and easy to calculate at the point of care
Good correlation with stone-free rates and surgical difficulty
Useful complement to Guy's Stone Score and other nephrolithometry systems
Helps standardize reporting of stone complexity in endourology literature

Last Comprehensive Review: 2026

Related Tools

PADUA Prediction Score
Urology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.